Aptose Biosciences, Inc.

Aptose Biosciences, Inc. company information, Employees & Contact Information

Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies. CG-806, our oral mutation-agnostic FLT3/BTK inhibitor, is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments. CG-806 is also being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML), including the emerging populations resistant to approved targeted therapies. APTO-253, our first-in-class MYC Inhibitor, is being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Company Details

Employees
31
Founded
-
Address
12770 High Bluff Drive,
Phone
416-798-1200
Email
in****@****era.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
San Diego, California
Looking for a particular Aptose Biosciences, Inc. employee's phone or email?

Aptose Biosciences, Inc. Questions

News

Aptose’s Tuspetinib Exceeds Expectations When Combined with - GlobeNewswire

Aptose’s Tuspetinib Exceeds Expectations When Combined with GlobeNewswire

Aptose Provides Corporate Updates - Yahoo Finance

Aptose Provides Corporate Updates Yahoo Finance

Aptose Faces Nasdaq Exit: What This Means for Investors and Trading Options - Stock Titan

Aptose Faces Nasdaq Exit: What This Means for Investors and Trading Options Stock Titan

Aptose Biosciences Inc. Announces Reverse Share Split to Enhance Compliance with Nasdaq Listing Requirements - Nasdaq

Aptose Biosciences Inc. Announces Reverse Share Split to Enhance Compliance with Nasdaq Listing Requirements Nasdaq

Aptose and Hanmi Pharmaceutical Extend Loan Agreement to - GlobeNewswire

Aptose and Hanmi Pharmaceutical Extend Loan Agreement to GlobeNewswire

Aptose Reports Second Quarter 2025 Results - Yahoo Finance

Aptose Reports Second Quarter 2025 Results Yahoo Finance

Aptose Biosciences Receives Extension from Nasdaq to Demonstrate Compliance with Listing Requirements - Quiver Quantitative

Aptose Biosciences Receives Extension from Nasdaq to Demonstrate Compliance with Listing Requirements Quiver Quantitative

Aptose Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirements - Nasdaq

Aptose Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirements Nasdaq

Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders - Yahoo Finance

Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders Yahoo Finance

Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee - GlobeNewswire

Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee GlobeNewswire

Aptose Common Shares to Delist from Nasdaq as of April 2, 2025 - Yahoo Finance

Aptose Common Shares to Delist from Nasdaq as of April 2, 2025 Yahoo Finance

Aptose Reports First Quarter 2025 Results - Yahoo Finance

Aptose Reports First Quarter 2025 Results Yahoo Finance

Aptos price today, APT to USD live price, marketcap and chart - CoinMarketCap

Aptos price today, APT to USD live price, marketcap and chart CoinMarketCap

Aptos Price: APT Live Price Chart, Market Cap & News Today - CoinGecko

Aptos Price: APT Live Price Chart, Market Cap & News Today CoinGecko

Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial - Yahoo Finance

Aptose Provides Clinical Update for the Tuspetinib-based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial Yahoo Finance

Aptose Announces Results from Special Meeting of Shareholders - Yahoo Finance

Aptose Announces Results from Special Meeting of Shareholders Yahoo Finance

Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023 - Yahoo Finance

Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023 Yahoo Finance

Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th - Yahoo Finance

Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th Yahoo Finance

Top Aptose Biosciences, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant